Is Purple Biotech Stock a Good Investment?
Purple Biotech Investment Advice | PPBT |
- Examine Purple Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Purple Biotech's leadership team and their track record. Good management can help Purple Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Purple Biotech's business and its evolving consumer preferences.
- Compare Purple Biotech's performance and market position to its competitors. Analyze how Purple Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Purple Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Purple Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Purple Biotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Purple Biotech is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Purple Biotech Stock
Researching Purple Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.35. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Purple Biotech recorded earning per share (EPS) of 81.0. The entity last dividend was issued on the 21st of August 2020. The firm had 1:20 split on the 17th of September 2024.
To determine if Purple Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Purple Biotech's research are outlined below:
| Purple Biotech is way too risky over 90 days horizon | |
| Purple Biotech appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (19.88 M) with loss before overhead, payroll, taxes, and interest of (120 K). | |
| Purple Biotech currently holds about 36.02 M in cash with (19.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.0. | |
| Purple Biotech has a frail financial position based on the latest SEC disclosures | |
| Latest headline from zacks.com: PPBT Stock Surges 150 percent on Superior Efficacy of PDAC Combo Therapy |
Purple Biotech Quarterly Liabilities And Stockholders Equity |
|
Purple Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Purple Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Purple Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Purple Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Purple Biotech's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-21 | 2024-03-31 | -0.19 | -0.14 | 0.05 | 26 | ||
2023-08-22 | 2023-06-30 | -0.3 | -0.25 | 0.05 | 16 | ||
2022-11-08 | 2022-09-30 | -0.21 | -0.27 | -0.06 | 28 | ||
2024-08-20 | 2024-06-30 | -0.16 | -0.0869 | 0.0731 | 45 | ||
2023-02-08 | 2022-12-31 | -0.25 | -0.33 | -0.08 | 32 | ||
2020-08-11 | 2020-06-30 | -0.1 | -0.01 | 0.09 | 90 | ||
2018-08-29 | 2018-06-30 | -0.1 | -0.01 | 0.09 | 90 | ||
2023-05-16 | 2023-03-31 | -0.36 | -0.25 | 0.11 | 30 |
Know Purple Biotech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Purple Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Purple Biotech backward and forwards among themselves. Purple Biotech's institutional investor refers to the entity that pools money to purchase Purple Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sound Income Strategies | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Kingswood Wealth Advisors Llc | 2024-09-30 | 0.0 | Wealth Advisors Of Iowa, Llc | 2024-09-30 | 0.0 | Raymond James & Associates | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 0.0 | Hrt Financial Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 158 K | Virtu Financial Llc | 2024-06-30 | 19.3 K |
Purple Biotech's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.12 M.Market Cap |
|
Purple Biotech's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | 0.60 | 0.63 |
Determining Purple Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Purple Biotech is a good buy. For example, gross profit margin measures Purple Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Purple Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Purple Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Purple Biotech. Check Purple Biotech's Beneish M Score to see the likelihood of Purple Biotech's management manipulating its earnings.
Evaluate Purple Biotech's management efficiency
Purple Biotech has return on total asset (ROA) of (0.2925) % which means that it has lost $0.2925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4467) %, meaning that it created substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.63 in 2024, whereas Return On Tangible Assets are likely to drop (0) in 2024. At this time, Purple Biotech's Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 964.8 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.15 | 0.15 | |
| Tangible Book Value Per Share | 0.03 | 0.03 | |
| Enterprise Value Over EBITDA | (0.27) | (0.29) | |
| Price Book Value Ratio | 0.59 | 0.49 | |
| Enterprise Value Multiple | (0.27) | (0.29) | |
| Price Fair Value | 0.59 | 0.49 | |
| Enterprise Value | 6.1 M | 11 M |
Purple Biotech's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 0.384 |
Basic technical analysis of Purple Stock
As of the 4th of December, Purple Biotech holds the Risk Adjusted Performance of 0.0326, semi deviation of 7.92, and Coefficient Of Variation of 3324.52. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Purple Biotech, as well as the relationship between them.Purple Biotech's Outstanding Corporate Bonds
Purple Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Purple Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Purple bonds can be classified according to their maturity, which is the date when Purple Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Purple Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Purple Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0326 | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 8.11 | |||
| Semi Deviation | 7.92 | |||
| Downside Deviation | 8.16 | |||
| Coefficient Of Variation | 3324.52 | |||
| Standard Deviation | 20.26 | |||
| Variance | 410.51 | |||
| Information Ratio | 0.0245 | |||
| Jensen Alpha | 0.8633 | |||
| Total Risk Alpha | (2.14) | |||
| Sortino Ratio | 0.0608 | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 32.62 | |||
| Value At Risk | (13.78) | |||
| Potential Upside | 13.36 | |||
| Downside Variance | 66.64 | |||
| Semi Variance | 62.68 | |||
| Expected Short fall | (10.89) | |||
| Skewness | 6.33 | |||
| Kurtosis | 46.88 |
| Risk Adjusted Performance | 0.0326 | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 8.11 | |||
| Semi Deviation | 7.92 | |||
| Downside Deviation | 8.16 | |||
| Coefficient Of Variation | 3324.52 | |||
| Standard Deviation | 20.26 | |||
| Variance | 410.51 | |||
| Information Ratio | 0.0245 | |||
| Jensen Alpha | 0.8633 | |||
| Total Risk Alpha | (2.14) | |||
| Sortino Ratio | 0.0608 | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 32.62 | |||
| Value At Risk | (13.78) | |||
| Potential Upside | 13.36 | |||
| Downside Variance | 66.64 | |||
| Semi Variance | 62.68 | |||
| Expected Short fall | (10.89) | |||
| Skewness | 6.33 | |||
| Kurtosis | 46.88 |
Consider Purple Biotech's intraday indicators
Purple Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Purple Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Purple Biotech Corporate Filings
6K | 3rd of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 31st of July 2024 Other Reports | ViewVerify | |
| 22nd of July 2024 Other Reports | ViewVerify |
Purple Stock media impact
Far too much social signal, news, headlines, and media speculation about Purple Biotech that are available to investors today. That information is available publicly through Purple media outlets and privately through word of mouth or via Purple internal channels. However, regardless of the origin, that massive amount of Purple data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Purple Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Purple Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Purple Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Purple Biotech alpha.
Purple Biotech Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Purple Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Purple Biotech Corporate Management
| MA CPA | Chief Officer | Profile | |
| Fabien Sebille | Chief Officer | Profile | |
| Michael Schickler | Head Affairs | Profile | |
| LLM BSc | Vice Operations | Profile | |
| Ido Morpurgo | VP Operations | Profile | |
| Nir Livneh | VP Affairs | Profile |
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.